Search results for "hypertriglyceridemia"

showing 10 items of 82 documents

“The Linosa Study”: Epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate

2009

Abstract Background and aims Growing evidence suggests that the metabolic syndrome (MetS) has both a genetic and environmental basis. To evaluate the possibility of a further genetic analysis, we estimated prevalence rates and heritabilities for the MetS and its individual traits in the adult population of Linosa, a small and isolated Italian Island in the southern-central part of the Mediterranean Sea. Methods and results The Linosa Study (LiS) group consisted of 293 Caucasian native subjects from 51 families (123 parents; 170 offsprings). The MetS was defined according to NCEP/ATP III criteria and the following prevalence rates were calculated: hyperglycaemia 20.3%; central obesity 34.9%;…

Blood GlucoseMaleSettore MED/09 - Medicina InternaGenetic LinkageEndocrinology Diabetes and MetabolismPrevalenceMedicine (miscellaneous)Settore MED/13 - EndocrinologiaGenetic Linkage; Young Adult; Age Factors; Metabolic Syndrome X; Cholesterol HDL; Hypertriglyceridemia; Sex Factors; Humans; Aged; Italy; Blood Glucose; Smoking; European Continental Ancestry Group; Adult; Middle Aged; Insulin Resistance; Adolescent; Male; FemaleSettore MED/49 - Scienze Tecniche Dietetiche ApplicateMetabolic SyndromeHypertriglyceridemiaeducation.field_of_studySettore M-EDF/01 - Metodi e Didattiche delle Attivita' MotorieNutrition and DieteticsMetabolic Syndrome XSmokingAge FactorsMiddle AgedCholesterolItalyAdolescent; Adult; Age Factors; Aged; Blood Glucose; Cholesterol HDL; European Continental Ancestry Group; Female; Genetic Linkage; Humans; Hypertriglyceridemia; Insulin Resistance; Italy; Male; Metabolic Syndrome X; Middle Aged; Sex Factors; Smoking; Young AdultFemaleCardiology and Cardiovascular MedicineGenetic isolateAdultmedicine.medical_specialtyWaistHDLAdolescentEuropean Continental Ancestry GroupPopulationBiologyWhite PeopleYoung AdultSex FactorsInsulin resistanceInternal medicinemedicineHumanseducationAgedCholesterol HDLnutritional and metabolic diseasesmetabolic syndromeHeritabilityInsulin resistanceMetabolic syndromeObesityHeritabilitymedicine.diseaseObesityEndocrinologySettore MED/03 - Genetica MedicaInsulin ResistanceMetabolic syndromeDemographyNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabet…

2018

Este artículo se encuentra disponible en la siguiente URL: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-documento-consenso-sociedad-espanola-arteriosclerosis-S0214916818300846 This is the pre-peer reviewed version of the following article: Ruiz-García, A., Arranz-Martínez, E., Morón-Merchante, I., Pascual-Fuster, V., Tamarit, JJ., Trias-Villagut, F. et al. (2018). Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. Clínica e Investigación en Arteriosclerosis, vol. 30, supl. 1 (julio), pp. 1-19, which has been published in final form …

Blood pressure controlmedicine.medical_specialtyHipertensión.FarmacologíaEnfermedad cardiovascularDisease030204 cardiovascular system & hematologyDiabetes - Farmacoterapia.Enfermedades cardiovasculares - Factores de riesgo - Tratamiento.Diabetes - Chemotherapy.03 medical and health sciencesTratamiento médicoCardiovascular system - Diseases - Risk factors - Treatment.0302 clinical medicineDiabetes mellitusHypertension.MedicinePharmacology (medical)Lipid controlHypoglycemic drugs030212 general & internal medicineIntensive care medicineInhibidores de agregación plaquetariabusiness.industryHypertriglyceridemiaType 2 Diabetes Mellitusnutritional and metabolic diseasesArteriosclerosismedicine.diseaseDiabetes mellitus tipo 2Cardiology and Cardiovascular Medicinebusiness
researchProduct

Cluster-determinant 36 (CD36) impacts on vitamin E postprandial response

2014

International audience; Scope: A single nucleotide polymorphism in the cluster determinant 36 (CD36) gene has recently been associated with plasma alpha-tocopherol concentration, suggesting a possible role of this protein in vitamin E intestinal absorption or tissue uptake. Methods and results: To investigate the involvement of CD36 in vitamin E transport, we first evaluated the effect of CD36 on alpha- and gamma-tocopherol transmembrane uptake and efflux using transfected HEK cells. gamma-Tocopherol postprandial response was then assessed in CD36-deficient mice compared with wild-type mice, after the mice had been fully characterized for their alpha -tocopherol, vitamin A and lipid plasma,…

CD36 AntigensMaleGenetically modified mouseVitaminmedicine.medical_specialtyBioavailability[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionCD36medicine.medical_treatmentalpha-TocopherolBiologyPolymorphism Single NucleotideIntestinal absorptionMice03 medical and health scienceschemistry.chemical_compoundInternal medicinemedicineAnimalsHumansTransgenic miceVitamin ATriglyceridesComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesgamma-TocopherolIntestinal absorptionVitamin E030302 biochemistry & molecular biologyHypertriglyceridemiaLipid metabolismLipid MetabolismPostprandial Periodmedicine.disease[SDV.AEN] Life Sciences [q-bio]/Food and NutritionCholesterolHEK293 CellsEndocrinologyPostprandialLiverchemistrybiology.proteinFemalelipids (amino acids peptides and proteins)CD36[SDV.AEN]Life Sciences [q-bio]/Food and NutritionFood ScienceBiotechnologyMolecular Nutrition & Food Research
researchProduct

Luminal Lipid Regulates CD36 Levels and Downstream Signaling to Stimulate Chylomicron Synthesis

2011

International audience; The membrane glycoprotein CD36 binds nanomolar concentrations of long chain fatty acids (LCFA) and is highly expressed on the luminal surface of enterocytes. CD36 deficiency reduces chylomicron production through unknown mechanisms. In this report, we provide novel insights into some of the underlying mechanisms. Our in vivo data demonstrate that CD36 gene deletion in mice does not affect LCFA uptake and subsequent esterification into triglycerides by the intestinal mucosa exposed to the micellar LCFA concentrations prevailing in the intestine. In rodents, the CD36 protein disappears early from the luminal side of intestinal villi during the postprandial period, but …

CD36 AntigensMaleMTPCD36[SDV]Life Sciences [q-bio]BiochemistryMicrosomal triglyceride transfer proteinMice0302 clinical medicineIntestinal mucosaCricetinaeChylomicronsLipoproteinHypertriglyceridemiaMice Knockout0303 health sciencesMitogen-Activated Protein Kinase 3biologyPostprandial PeriodLipid-binding ProteinIntestineApoB48ERKmedicine.anatomical_structurePostprandialBiochemistrylipids (amino acids peptides and proteins)Apolipoprotein B-48MAP Kinase Signaling SystemEnterocyteCHO CellsChylomicron03 medical and health sciencesCricetulusparasitic diseasesmedicineAnimalsRats WistarMolecular Biology030304 developmental biologyUbiquitinationLipid absorptionLipid metabolismCell BiologyLipid MetabolismRatsEnterocytesMetabolismbiology.proteinApolipoprotein B-48CD36[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryChylomicron
researchProduct

From fatty-acid sensing to chylomicron synthesis: Role of intestinal lipid-binding proteins

2013

International audience; Today, it is well established that the development of obesity and associated diseases results, in part, from excessive lipid intake associated with a qualitative imbalance. Among the organs involved in lipid homeostasis, the small intestine is the least studied even though it determines lipid bioavailability and largely contributes to the regulation of postprandial hyperlipemia (triacylglycerols (TG) and free fatty acids (FFA)). Several Lipid-Binding Proteins (LBP) are expressed in the small intestine. Their supposed intestinal functions were initially based on what was reported in other tissues, and took no account of the physiological specificity of the small intes…

CD36 Antigensmedicine.medical_specialtyCD36[SDV]Life Sciences [q-bio]Intestinal adaptationBiologyFatty Acid-Binding ProteinsBiochemistryIntestinal absorptionChylomicronInsulin resistanceLipid-binding proteinsInternal medicineLipid dropletChylomicronsIntestine SmallmedicineAnimalsHumansCd36chemistry.chemical_classificationHypertriglyceridemiaFatty AcidsFatty acidGeneral Medicinemedicine.diseaseLipid MetabolismDietary FatsSmall intestine3. Good healthmedicine.anatomical_structureEndocrinologyEnterocyteschemistryBiochemistryIntestinal AbsorptionIntestinal lipid sensingbiology.proteinlipids (amino acids peptides and proteins)[SDV.AEN]Life Sciences [q-bio]/Food and NutritionChylomicron
researchProduct

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strat…

2021

Abstract Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiova…

CHOLESTERYL ESTER TRANSFERTO-MODERATE HYPERTRIGLYCERIDEMIALipoprotein remnants030204 cardiovascular system & hematologyBioinformaticsResidual riskBrain Ischemiachemistry.chemical_compoundVoeding Metabolisme en Genomica0302 clinical medicineIschaemic strokeAcademicSubjects/MED00200Myocardial infarctionLOW-GRADE INFLAMMATIONALL-CAUSE MORTALITY[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism0303 health sciencesAtherosclerotic cardiovascular diseasedigestive oral and skin physiology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseMetabolism and Genomics3. Good healthStrokeLOW-DENSITY LIPOPROTEINSCardiovascular DiseasesMetabolisme en GenomicaCORONARY-ARTERY-DISEASENutrition Metabolism and GenomicsCardiology and Cardiovascular MedicineB-CONTAINING LIPOPROTEINSLipoproteinsTriglyceride-rich lipoproteinsHEART-DISEASE03 medical and health sciencesSpecial ArticleVoedingmedicineHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIATriglycerides030304 developmental biologyNutritionVLAGTriglyceridebusiness.industryAPO-Bmedicine.diseaseAtherosclerosisResidual riskIncreased riskchemistry3121 General medicine internal medicine and other clinical medicineEuropean atherosclerosis societybusinessLipoprotein
researchProduct

Diagnostic algorithm for familial chylomicronemia syndrome

2016

International audience; Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia often associated with recurrent episodes of pancreatitis. The recognition and correct diagnosis of the disease is challenging due to its rarity, and to the lack of specificity of signs and symptoms. Lipid experts, endocrinologists, gastroenterologists, pancreatologists, and general practitioners may encounter patients who potentially have FCS. Therefore, cooperation between experts and improved knowledge of FCS is essential in improving the diagnosis. Currently, a consensus on best practice for the diagnosis of FCS is lacking. Methods: Aiming to def…

Chylomicrons; Familial chylomicronemia syndrome; Hyperlipoproteinemia; Lipoprotein lipase deficiency; Pancreatitis; Biomarkers; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type I; Lipids; Lipoprotein Lipase; Phenotype; Practice Guidelines as Topic; Predictive Value of Tests; Prognosis; Algorithms; Critical Pathways; DNA Mutational Analysis; Decision Support Techniques; Mutation; Internal Medicine; Cardiology and Cardiovascular MedicineSettore MED/09 - Medicina InternaACUTE-PANCREATITIS[SDV]Life Sciences [q-bio]DNA Mutational AnalysisPredictive Value of TestDisease030204 cardiovascular system & hematologyVARIANTSDecision Support Technique0302 clinical medicineDOMAINGenetic MarkerBINDINGChylomicronsHYPERTRIGLYCERIDEMICMedicine030212 general & internal medicinePANCREATITISLipoprotein lipase deficiencyGeneral MedicineFamilial ChylomicronemiaLipidPrognosisLipids3. Good healthAlgorithmDEFICIENCYPhenotypeCritical PathwayPractice Guidelines as TopicCritical PathwaysHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAlgorithmAlgorithmsHumanGenetic MarkersSevere hypertriglyceridemiaFamilial chylomicronemia syndromePrognosiSigns and symptomsLIPOPROTEIN-LIPASEHyperlipoproteinemiaCLASSIFICATIONDecision Support TechniquesSecondary careChylomicronDNA Mutational Analysi03 medical and health sciencesPredictive Value of TestsInternal MedicineMANAGEMENTHumansGenetic Predisposition to DiseasePancreatitibusiness.industryBiomarkerLipoprotein LipaseMutationbusinessBiomarkers
researchProduct

Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

2020

Background:Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the Microsomal Triglyceride Transfer Protein (MTP) approved as a novel drug for the management of Homozygous Familial Hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.Aims:The present review aims at summarizing the recent knowledge on lomitapide in the management of HoFH.Results:The efficacy and safety of lomitapide have been evaluated in several trials and it has been shown a reduction of the plasma levels of Low-Density Lipoprotein Cholesterol …

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemia030204 cardiovascular system & hematologyBiochemistryMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryMedicineHumans030212 general & internal medicinemedia_commonPharmacologybiologybusiness.industryAnticholesteremic AgentsOrganic ChemistryHypertriglyceridemiaPlasma levelsmedicine.diseaseLomitapideEuropeTolerabilitychemistrybiology.proteinMolecular MedicinePancreatitisBenzimidazolesHoFH – Lomitapide – LOWER Registry – MTP inhibition – MTP SNPsbusiness
researchProduct

Lipase maturation factor 1 is required for endothelial lipase activity

2011

Lipase maturation factor 1 (Lmf1) is an endoplasmic reticulum (ER) membrane protein involved in the posttranslational folding and/or assembly of lipoprotein lipase (LPL) and hepatic lipase (HL) into active enzymes. Mutations in Lmf1 are associated with diminished LPL and HL activities ("combined lipase deficiency") and result in severe hypertriglyceridemia in mice as well as in human subjects. Here, we investigate whether endothelial lipase (EL) also requires Lmf1 to attain enzymatic activity. We demonstrate that cells harboring a (cld) loss-of-function mutation in the Lmf1 gene are unable to generate active EL, but they regain this capacity after reconstitution with the Lmf1 wild type. Fur…

Endothelial lipaseSettore MED/09 - Medicina InternaCombined Lipase DeficiencyQD415-436PhospholipaseTransfectionBiochemistryChromatography Affinityphospholipasescombined lipase deficiencyMiceEndocrinologyAnimalsHumansWithdrawals/RetractionsLipaseResearch ArticlesHypertriglyceridemiaLipoprotein lipasecombined lipase deficiency; endoplasmic reticulum; hepatic; metabolism; phospholipasesbiologyEndoplasmic reticulumWild typeMembrane ProteinsLipaseCell BiologyFibroblastsMolecular biologyLipoprotein Lipaseendoplasmic reticulumElectroporationHEK293 CellsMutationbiology.proteinHepatic lipasehepaticmetabolismPlasmidscombined lipase deficiencyJournal of Lipid Research
researchProduct

Action of an extract from the seeds of Fraxinus excelsior L. on metabolic disorders in hypertensive and obese animal models.

2014

Nuzhenide and GI3, the principal secoiridoids of an extract obtained from the seeds of Fraxinus excelsior L. (FXE), are believed to be the active compounds responsible for the previously reported hypoglycemic effects of this extract. In this study, the effects of FXE were studied in two animal models which are representative of metabolic disorders: spontaneously hypertensive rats (SHR) and obese Zucker rats. SHR were acutely treated (oral gavage) with different doses of FXE. In addition, SHR and Zucker rats were chronically fed (20 or 5 weeks, respectively) with standard chow supplemented with FXE. Acute treatment with FXE (200 mg per kg body weight) decreased systolic blood pressure as in …

Fraxinus excelsior L.Blood GlucoseMalemedicine.medical_specialtyBlood PressureOral gavageInsulin resistanceInternal medicineRats Inbred SHRmedicineAnimalsHumansHypoglycemic AgentsInsulinObesitybusiness.industryPlant ExtractsHypertriglyceridemiaCaptoprilGeneral Medicinemedicine.diseaseObesityRatsRats ZuckerDisease Models AnimalEndocrinologyFraxinusHypertensionSeedsHypoglycemic EffectsMetabolic syndromebusinessFood Sciencemedicine.drugFoodfunction
researchProduct